Press Releases
November 2008
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
Thursday 20 Nov, 2008
Teva Provides Update on Generic Pulmicort Respules® Launch
Thursday 20 Nov, 2008
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Wednesday 19 Nov, 2008
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicin
Tuesday 18 Nov, 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Tuesday 18 Nov, 2008
Daiichi Sankyo and Biota (ASX:BTA) start Phase III trials in Asia for next generation Relenza product
Monday 17 Nov, 2008
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Monday 17 Nov, 2008
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Monday 17 Nov, 2008
ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders
Friday 14 Nov, 2008
FDA Approves BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
Friday 14 Nov, 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Thursday 13 Nov, 2008
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
Wednesday 12 Nov, 2008
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
Wednesday 12 Nov, 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Tuesday 11 Nov, 2008
TNFerade(TM) Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer
Tuesday 11 Nov, 2008
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
Monday 10 Nov, 2008
Lab21 Expands International Business with Launch into India with a Million Dollar Syphilis Testing Agreement
Monday 10 Nov, 2008
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Sunday 9 Nov, 2008
Winston Laboratories, Inc. Announces Licensing Agreement with sanofi-aventis Canada Inc. in Canada
Friday 7 Nov, 2008
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Thursday 6 Nov, 2008
Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)
Wednesday 5 Nov, 2008
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
Wednesday 5 Nov, 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Tuesday 4 Nov, 2008
Cardiovascular Systems Signs Merger Agreement
Tuesday 4 Nov, 2008
Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Monday 3 Nov, 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Monday 3 Nov, 2008
CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Monday 3 Nov, 2008
Copyright 2008 Ochre media. All rights reserved.